1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Amer Soc Nephrol 2004; 15: 2208-2218.
2. Moe SM, Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product. Am J Nephrol 2003; 23: 369-79.
3. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 2005; 67: 1179-1187.
4. Slinin Y, Foley RN, Collins AJ. Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study. J Am Soc Nephrol 2005; 16: 1788-93.
5. Moe S, Drüeke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; (in press):
6. Slatopolsky E, Caglar S, Pannell JP, et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971; 50: 492-499.
7. Llach F, Massry SG, Koffler A. Secondary hyperparathyroidism in early renal failure: role of phosphate retention. Kidney Int 1977; 12: 459-63.
8. Saito H, Maeda A, Ohtomo SI, et al. Circulating FGF-23 is regulated by 1a,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2004;
9. Sato T, Tominaga Y, Ueki T, et al. Total parathyroidectomy reduces elevated circulating fibroblast growth factor 23 in advanced secondary hyperparathyroidism. Am J Kidney Dis 2004; 44: 481-7.
10. Imanishi Y, Inaba M, Nakatsuka K, et al. FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004; 65: 1943-6.
11. Kolek OI, Hines ER, Jones MD, et al. 1 alpha,25-Dihydroxyvitamin D-3 upregulates FGF23 gene expression in bone: the final link in a renal- gastrointestinal-skeletal axis that controls phosphate transport. Amer J Physiol Gastrointest L 2005; 289: G1036-G1042.
12. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003; 64: 2272-9.
13. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab 2005; 90: 1519-1524.
14. Saito H, Maeda A, Ohtomo S, et al. Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo. J Biol Chem 2005; 280: 2543-9.
15. Perwad F, Azam N, Zhang MY, Yamashita T, Tenenhouse HS, Portale AA. Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice. Endocrinology 2005; 146: 5358-64.
16. Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Amer Soc Nephrol 2005; 16: 2205-2215.
17. Shigematsu T, Kazama JJ, Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency. Am J Kidney Dis 2004; 44: 250-6.
18. Nakanishi S, Kazama JJ, NiiKono T, et al. Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005; 67: 1171-1178.
19. Kazama JJ, Sato F, Omori K, et al. Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients. Kidney Int 2005; 67: 1120-1125.
20. Hsu CY, Chertow GM. Elevations of serum phosphorus and potassium in mild to moderate chronic renal insufficiency. Nephrol Dial Transplant 2002; 17: 1419-25.
21. Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D-3. Cell 1999; 96: 507-515.
22. Zehnder D, Bland R, Walker EA, et al. Expression of 25-hydroxyvitamin D-3-1 alpha-hydroxylase in the human kidney. J Amer Soc Nephrol 1999; 10: 2465-2473.
23. Lucas PA, Brown RC, Woodhead JS, Colesi GA. 1,25 dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure : effect of simultaneous protein and phosphorus restriction. Clin Nephrol 1986; 25: 7-10.
24. Cunningham J, Makin H. How important is vitamin D deficiency in uraemia ? (Editorial Comment). Nephrol Dial Transplant 1997; 12: 16-18.
25. Ghazali A, Fardellone P, Pruna A, et al. Is low plasma 25-(OH)vitamin D a major risk factor for hyperparathyroidism and Looser's zones independent of calcitriol? Kidney Int 1999; 55: 2169-2177.
26. Glorieux G, Hsu CH, de Smet R, et al. Inhibition of calcitriol-induced monocyte CD14 expression by uremic toxins: role of purines. J Am Soc Nephrol 1998; 9: 1826-31.
27. Patel SR, Ke HQ, Vanholder R, Koenig RJ, Hsu CH. Inhibition of calcitriol receptor binding to vitamin D response elements by uremic toxins. J Clin Invest 1995; 96: 50-59.
28. Dusso AS. Vitamin D receptor: Mechanisms for vitamin D resistance in renal failure. Kidney Int Suppl 2003; 6-9.
29. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993; 92: 1436-1442.
30. Patel S, Ke HQ, Vanholder R, Hsu CH. Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate. Kidney Int 1994; 46: 129-133.
31. Garfia B, Canadillas S, Canalejo A, et al. Regulation of parathyroid vitamin D receptor expression by extracellular calcium. J Amer Soc Nephrol 2002; 13: 2945-2952.
32. SelaBrown A, Russell J, Koszewski NJ, Michalak M, NavehMany T, Silver J. Calreticulin inhibits vitamin D's action on the PTH gene in vitro and may prevent vitamin D's effect in vivo in hypocalcemic rats. Mol Endocrinol 1998; 12: 1193-1200.
33. Brown AJ, Zhong M, Finch J, et al. Rat calcium-sensing receptor is regulated by vitamin D but not by calcium. Am J Physiol 1996; 270: F454-F460.
34. Rogers KV, Dunn CK, Conklin RL, et al. Calcium receptor messenger ribonucleic acid levels in the parathyroid glands and kidney of vitamin D-deficient rats are not regulated by plasma calcium or 1,25-dihydroxyvitamin D3. Endocrinology 1995; 136: 499-504.
35. Silver J, Sela SB, Naveh-Many T. Regulation of parathyroid cell proliferation. Curr Opin Nephrol Hypertens 1997; 6: 321-326.
36. Szabo A, Merke J, Beier E, Mall G, Ritz E. 1,25(OH)2 vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 1989; 35: 1045-1056.
37. Taniguchi M, Tokumoto M, Matsuo D, Tsuruya K, Hirakata H, Iida M. Parathyroid growth and regression in experimental uremia. Kidney Int 2006; 69: 464-470.
38. Fukagawa M, Kaname S-Y, Igarashi T, Ogata E, Kurokawa K. Regulation of parathyroid hormone synthesis in chronic renal failure in rats. Kidney Int 1991; 39: 874-881.
39. Nygren P, Larsson R, Johannson H, Ljunghall S, Rastad J, Akerstrom G. 1,25 (OH)2 D3 inhibits hormone secretion and proliferation but not functional dedifferentiation of cultured bovine parathyroid cells. Calcif Tissue Int 1988; 43: 213-218.
40. Kremer R, Bolivar I, Goltzman D, Hendy GN. Influence of calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-oncogene expression in primary cultures of bovine parathyroid cells. Endocrinology 1989; 125: 935-941.
41. Ishimi Y, Russel J, Sherwood LM. Regulation by calcium and 1,25-(OH)2D3 of cell proliferation and function of bovine parathyroid cells in culture. J Bone Min Res 1990; 5: 755-760.
42. Roussanne MC, Lieberherr M, Souberbielle JC, Sarfati E, Drueke T, Bourdeau A. Human parathyroid cell proliferation in response to calcium, NPS R-467, calcitriol and phosphate. Eur J Clin Invest 2001; 31: 610-6.
43. Fernandez A, Fibla J, Betriu A, Piulats JM, Almirall J, Montoliu J. Association between vitamin D receptor gene polymorphism and relative hypoparathyroidism in patients with chronic renal failure. J Am Soc Nephrol 1997; 8: 1546-1552.
44. Messa P, Vallone C, Mioni G, et al. Direct in vivo assessment of parathyroid hormone-calcium relationship curve in renal patients. Kidney Int 1994; 46: 1713-1720.
45. Aterini S, Salvadori M, Ippolito E, et al. The role of vitamin D receptor alleles in the secondary hyperparathyroidism of hemodialysis patients. J Nephrol 1996; 9: 201-206.
46. Nagaba Y, Heishi M, Tazawa H, Tsukamoto Y, Kobayashi Y. Vitamin D receptor gene polymorphisms affect secondary hyperparathyroidism in hemodialyzed patients. Am J Kidney Dis 1998; 32: 464-9.
47. Yokoyama K, Shigematsu T, Tsukada T, et al. Apa I polymorphism in the vitamin D receptor gene may affect the parathyroid response in Japanese with end-stage renal disease. Kidney Int 1998; 53: 454-458.
48. Schmidt S, Chudek J, Karkoska H, et al. The BsmI vitamin D-recptor polymorphism and secondary hyperparathyroidism (Letter). Nephrol Dial Transplant 1997; 12: 1771-1772.
49. Torres A, Machado M, Concepcion MT, et al. Influence of vitamin D receptor genotype on bone mass changes after renal transplantation. Kidney Int 1996; 50: 1726-1733.
50. Carling T, Kindmark A, Hellman P, Holmberg L, Åkerström G, Rastad J. Vitamin D receptor alleles b, a, and T: risk factors for sporadic primary hyperparathyroidism (HPT) but not HPT of uremia of MEN 1. Biochem Biophys Res Commun 1997; 231: 329-332.
51. Morrison NA, Qi JC, Tokita A, et al. Prediction of bone density from vitamin D receptor alleles. Nature 1994; 367: 284-287.
52. Hawa NS, Cockerill FJ, Vadher S, et al. Identification of a novel mutation in hereditary vitamin D resistant rickets causing exon skipping. Clin Endocrinol 1996; 45: 85-92.
53. Kawata T, Imanishi Y, Kobayashi K, et al. Direct in vitro evidence of extracellular Ca2+-induced amino-terminal truncation of human parathyroid hormone (1- 84) by human parathyroid cells. J Clin Endocrinol Metab 2005; 90: 5774-5778.
54. D'Amour P, Brossard JH, Rousseau L, et al. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005; 68: 998-1007.
55. Moyses RMA, Pereira RC, dosReis LM, Sabbaga E, Jorgetti V. Dynamic tests of parathyroid hormone secretion using hemodialysis and calcium infusion cannot be compared. Kidney Int 1999; 56: 659-665.
56. Brown EM. Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extracellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 1983; 56: 572-581.
57. Gogusev J, Duchambon P, Hory B, Giovannini M, Sarfati E, Drüeke TB. Depressed expression of calcium receptor in parathyroid gland tissue of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 1997; 51: 328-336.
58. Kifor O, Moore FD, Wang P, et al. Reduced immunostaining for the extracellular Ca2+ - sensing receptor in primary and uremic secondary hyperparathyroidism. J Clin Endocrinol Metab 1996; 81: 1598-1606.
59. Almadén Y, Hernandez A, Torregrosa V, et al. High phosphate level directly stimulates parathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Amer Soc Nephrol 1998; 9: 1845-1852.
60. Gogusev J, Duchambon P, Stoermann-Chopard C, Giovannini M, Sarfati E, Drüeke TB. De novo expression of transforming growth factor-a in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism. Nephrol Dial Transplant 1996; 11: 2155-2162.
61. Canadillas S, Canalejo A, Santamaria R, et al. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans. J Amer Soc Nephrol 2005; 16: 2190-2197.
62. Lewin E, Garfia B, Almaden Y, Rodriguez M, Olgaard K. Autoregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats. Kidney Int 2003; 64: 63-70.
63. Goodman WG, Veldhuis JD, Belin TR, VanHerle AJ, Juppner H, Salusky IB. Calcium-sensing by parathyroid glands in secondary hyperparathyroidism. J Clin Endocrinol Metab 1998; 83: 2765-2772.
64. Goodman WG, Belin TR, Salusky IB. In vivo assessments of calcium-regulated parathyroid hormone release in secondary hyperparathyroidism. Kidney Int 1996; 50: 1834-1844.
65. Felsenfeld AJ, Rodriguez M. Parathyroid gland function in hemodialysis patients. Semin Dial 1996; 9: 303-309.
66. Ouseph R, Leiser JD, Moe SM. Calcitriol and the parathyroid hormone-ionized calcium curve: a comparison of methodologic approaches. J Am Soc Nephrol 1996; 7: 497-505.
67. Naveh-Many T, Rahamimov R, Livni N, Silver J. Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 1995; 96: 1786-1793.
68. Mathias RS, Nguyen HT, Zhang MYH, Portale AA. Reduced expression of the renal calcium-sensing receptor in rats with experimental chronic renal insufficiency. J Amer Soc Nephrol 1998; 9: 2067-2074.
69. Wada M, Furuya Y, Sakiyama J, et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997; 100: 2977-83.
70. Wernerson A, Windholm SM, Svensson O, Reinholt FP. Parathyroid cell number and size in hypocalcemic young rats. APMIS 1991; 99: 1096-1102.
71. McGregor RR, Sarras MP, Houle H, Cohn DV. Primary monolayer culture of bovine parathyroids: effect of calcium, isoproterenol, and growth factors. Mol Cell Endocrinol 1983; 30: 313-328.
72. LeBoff MS, Rennke HG, Brown EM. Abnormal regulation of parathyroid cell secretion and proliferation in primary cultures of bovine parathyroid cells. Endocrinology 1983; 113: 277-284.
73. LeBoff MS, Shoback D, Brown EM, et al. Regulation of parathyroid hormone release and cytosolic calcium by extracellular calcium in dispersed and cultured bovine and pathological human parathyroid cells. J Clin Invest 1985; 75: 49-57.
74. Ridgeway RD, Hamilton JW, Gregor RRM. Characteristics of bovine parathyroid cell organoid in culture. In Vitro Cell Dev 1998; 22: 91-99.
75. Brandi ML, Fitzpatrick LA, Coon HG, Aurbach GD. Bovine parathyroid cell: cultures maintained for more than 140 population doublings. Proc Natl Acad Sci USA 1986; 83: 1709-1713.
76. Mithal A, Kifor O, Kifor I, et al. The reduced responsiveness of cultured bovine parathyroid cells to extracellular Ca2+ is associated with marked reduction in the expression of extracellular Ca2+-sensing receptor messenger ribonucleic acid and protein. Endocrinology 1995; 136: 3087-3092.
77. Brown AJ, Zhong M, Ritter CS, Brown EM, Slatopolsky E. Loss of calcium responsiveness in cultured parathyroid cells is associated with decreased calcium receptor expression. Biochem Biophys Res Commun 1995; 212: 861-867.
78. Brandi ML, Ornberg RL, Sakaguchi K, et al. Establishment and characterization of a clonal line of parathyroid endothelial cells. FASEB J 1990; 4: 3152-3158.
79. Sakaguchi K. Acidic fibroblast growth factor autocrine system as a mediator of calcium-regulated parathyroid cell growth. J Biol Chem 1992; 267: 24554-24562.
80. Roussanne M-C, Gogusev J, Hory B, et al. Persistence of Ca2+-sensing receptor expression in functionally active, long-term human parathyroid cell cultures. J Bone Min Res 1998; 13: 1-9.
81. Mizobuchi M, Hatamura I, Ogata H, et al. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency. J Am Soc Nephrol 2004; 15: 2579-87.
82. Chikatsu N, Fukumoto S, Takeuchi Y, et al. Cloning and characterization of two promoters for the human calcium-sensing receptor (CaSR) and changes of CaSR expression in parathyroid adenomas. J Biol Chem 2000; 275: 7553-7557.
83. Lundgren S, Carling T, Hjälm G, et al. Tissue distribution of human gp330/megalin, a putative Ca2+-sensing protein. J Histochem Cytochem 1997; 45: 383-392.
84. Martin DR, Ritter CS, Slatopolsky E, Brown AJ. Acute regulation of parathyroid hormone by dietary phosphate. Amer J Physiol Endocrinol Met 2005; 289: E729-E734.
85. Almadén Y, Canalejo A, Hernandez A, et al. Direct effect of phosphorus on parathyroid hormone secretion from whole rat parathyroid glands in vitro. J Bone Min Res 1996; 11: 970-976.
86. Nielsen PK, Feldt-Rasmussen U, Olgaard K. A direct effect of phosphate on PTH release from bovine parathyroid tissue slices but not from dispersed parathyroid cells. Nephrol Dial Transplant 1996; 11: 1762-1768.
87. Slatopolsky E, Finch J, Denda M, et al. Phosphorus restriction prevents parathyroid gland growth: high phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534-2540.
88. Almaden Y, Canalejo A, Ballesteros E, Anon G, Canadillas S, Rodriguez M. Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: Effect of extracellular phosphate. J Amer Soc Nephrol 2002; 13: 693-698.
89. Moallem E, Kilav R, Silver J, NavehMany T. RNA-protein binding and post-transcriptional regulation of parathyroid hormone gene expression by calcium and phosphate. J Biol Chem 1998; 273: 5253-5259.
90. SelaBrown A, Silver J, Brewer G, NavehMany T. Identification of AUF1 as a parathyroid hormone mRNA 3'-untranslated region-binding protein that determines parathyroid hormone mRNA stability. J Biol Chem 2000; 275: 7424-7429.
91. Slatopolsky E, Delmez E. Pathogenesis of secondary hyperparathyroidism. Miner Electrolyte Metab 1995; 21: 91-96.
92. Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K. Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 1995; 70: 242-248.
93. Takahashi F, Denda M, Finch JL, Brown AJ, Slatopolsky E. Hyperplasia of the parathyroid gland without secondary hyperparathyroidism. Kidney Int 2002; 61: 1332-1338.
94. Vicenti F, Arnaud SB, Recker R, et al. Parathyroid and bone response of the diabetic patient to uremia. Kidney Int 1984; 25: 677-682.
95. Aubia J, Serrano S, Mariosso L, et al. Osteodystrophy of diabetics in chronic dialysis: a histomorphometric study. Calcif Tissue Int 1988; 42: 297-301.
96. Pei Y, Hercz G, Greenwood C, et al. Renal osteodystrophy in diabetic patients. Kidney Int 1993; 44: 159-164.
97. Hernandez D, Concepcion MT, Lorenzo V, et al. Adynamic bone disease with negative aluminum staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 1994; 9: 517-523.
98. Panuccio V, Mallamaci F, Tripepi G, et al. Low parathyroid hormone and pentosidine in hemodialysis patients. Am J Kidney Dis 2002; 40: 810-5.
99. Jara A, Bover J, Felsenfeld AJ. Development of secondary hyperparathyroidism and bone disease in diabetic rats with renal failure. Kidney Int 1995; 47: 1746-1751.
100. Sugimoto T, Ritter C, Morrisey J, Hayes C, Slatopolsky E. Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 1990; 37: 1522-1527.
101. Hodsman AB, Sherrard D, Alfrey AC, et al. Bone aluminum and histomorphometric features of renal osteodystrophy. J Clin Endocrinol Metab 1982; 54: 539-546.
102. Cannata JB, Briggs JD, Junor BJR, Fell JS. The influence of aluminium on parathyroid hormone levels in hemodialysis patients. Proc Eur Dial Transplant Assoc 1982; 19: 244-247.
103. Kraut JA, Shinaberger JH, Singer FR, et al. Parathyroid hormone response to acute hypocalcemia in dialysis osteomalacia. Kidney Int 1983; 23: 725-730.
104. Llach F, Felsenfeld AJ, Coleman MD, Jr JJK, Pederson JA, Medlock TR. The natural course of dialysis osteomalacia. Kidney Int 1986; 29 (suppl 18): S74-S79.
105. Andress D, Felsenfeld AJ, Voigts A, Llach F. Parathyroid hormone response to hypocalcemia in hemodilaysis patients with osteomalacia. Kidney Int 1983; 24: 363-370.
106. Cann CE, Prussin SG, Gordan GS. Aluminum uptake by the parathyroid glands. J Clin Endocrinol Metab 1979; 49: 543-545.
107. Rodriguez M, Felsenfeld AJ, Llach F. The role of aluminum in the development of hypercalcemia in the rat. Kidney Int 1987; 31: 766-771.
108. Morrissey J, Slatopolsky S. Effect of aluminum on parathyroid hormone secretion. Kidney Int 1986; 29 (suppl 18): S41-S44.
109. Bourdeau AM, Plachot JJ, Cournot-Witmer G, Pointillart A, Balsan S, Sachs C. Parathyroid response to aluminum in vitro : ultratructural changes and PTH release. Kidney Int 1987; 31: 15-24.
110. Alfrey AC, Sedman A, Chan Y. The compartmentalization and metabolism of aluminum in uremic rats. J Lab Clin Med 1985; 105: 227-233.
111. Henry DA, Goodman WG, Nudelman RK, et al. Parenteral aluminum administration in the dog: I. Plasma kinetics, tissue levels, calcium metabolism, and parathyroid hormone. Kidney Int 1984; 25: 362-369.
112. Finch JL, Bergfeld M, Martin KJ, Chan YL, Teitelbaum S, Slatopolsky E. The effects of discontinuation of aluminum exposure on aluminum-induced osteomalacia. Kidney Int 1986; 30: 318-324.
113. DiazLopez JB, D'Haese PC, Noueven EJ, Lamberts LV, Cannata JB, Broe MED. Estudio del contenido de aluminio en paratiroides de ratas con insuficiencia renal e intoxicacion aluminica cronica. Nefrologia 1988; 8: 35-41.
114. Felsenfeld AJ, Rofdriguez M, Coleman M, Ross D, Llach F. Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease. Kidney Int 1989; 35: 1371-1378.
115. Liu W, Hellman P, Li Q, et al. Biosynthesis and function of all-trans- and 9-cis-retinoic acid in parathyroid cells. Biochem Biophys Res Commun 1996; 229: 922-929.
116. Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS. p21(WAF1) and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium. Kidney Int 2001; 60: 2109-2117.
117. Cordero JB, Cozzolino M, Lu Y, et al. 1,25-Dihydroxyvitamin D down-regulates cell membrane growth- and nuclear growth-promoting signals by the epidermal growth factor receptor. J Biol Chem 2002; 277: 38965-71.
118. Dusso AS, Pavlopoulos T, Naumovich L, et al. P21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth. Kidney Int 2001; 59: 855-865.
119. Cozzolino M, Lu Y, Sato T, et al. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease. Amer J Physiol Renal Physiol 2005; 289: F1096-F1102.
120. Matsushita H, Hara M, Endo Y, et al. Proliferation of parathyroid cells negatively correlates with expression of parathyroid hormone-related protein in secondary parathyroid hyperplasia. Kidney Int 1999; 55: 130-138.
121. Gunther T, Chen ZF, Kim J, et al. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 2000; 406: 199-203.
122. Correa P, Akerstrom G, Westin G. Underexpression of Gcm2, a master regulatory gene of parathyroid gland development, in adenomas of primary hyperparathyroidism. Clin Endocrinol (Oxf) 2002; 57: 501-5.
123. Mendes V, Jorgetti V, Nemeth J, et al. Secondary hyperparathyroidism in chronic haemodialysis patients: a clinico-pathologic study. Proc Europ Dial Transplant Assoc 1983; 20: 731-738.
124. Arnold A, Brown MF, Ureña P, Gaz RD, Sarfati E, Drüeke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest 1995; 95: 2047-2054.
125. Tominaga Y, Kohara S, Namii Y, et al. Clonal analysis of nodular parathyroid hyperplasia in renal hyperparathyroidism. World J Surg 1996; 20: 744-752.
126. Chudek J, Ritz E, Kovacs G. Genetic abnormalities in parathyroid nodules of uremic patients. Clin Cancer Res 1998; 4: 211-214.
127. Imanishi Y, Tahara H, Palanisamy N, et al. Clonal chromosomal defects in the molecular pathogenesis of refractory hyperparathyroidism of uremia. J Amer Soc Nephrol 2002; 13: 1490-1498.
128. Hsi ED, Zukerberg LR, Yang W-I, Arnold A. CyclinD1/PRAD1 expression in parathyroid adenomas: an immunohistochemical study. J Clin Endocrinol Metab 1996; 81: 1736-1739.
129. Tominaga Y, Tsuzuki T, Uchida K, et al. Expression of PRAD1 cyclin D1, retinoblastoma gene products, and Ki67 in parathyroid hyperplasia caused by chronic renal failure versus primary adenoma. Kidney Int 1999; 55: 1375-1383.
130. Brown AJ, Ritter CS, Finch JL, Slatopolsky EA. Decreased calcium-sensing receptor expression in hyperplastic parathyroid glands of uremic rats: Role of dietary phosphate. Kidney Int 1999; 55: 1284-1292.
131. Brown SB, Brierley TT, Palanisamy N, et al. Vitamin D receptor as a candidate tumor-suppressor gene in severe hyperparathyroidism of uremia. J Clin Endocrinol Metab 2000; 85: 868-872.
132. Degenhardt S, Toell A, Weideman W, Dotzenrath C, Spindler K-D, Grabensee B. Point mutations of the human parathyroid calcium receptor gene are not responsible for non-suppresible renal hyperparathyroidism. Kidney Intern 1998; 53: 556-561.
133. Miki H, Sumitomo M, Inoue H, Kita S, Monden Y. Parathyroid carcinoma in patients with chronic renal failure on maintenance hemodialysis. [Review] [10 refs]. Surgery 1996; 120: 897-901.
134. Djema AI, Mahmoud MD, Collin P, Heyman MF. Hyperparathyroïdie tertiaire: cancer parathyroïdien avec métastases hépatiques chez un hémodialysé. Néphrologie 1998; 19: 121-123.
135. Takami H, Kameyama K, Nagakubo I. Parathyroid carcinoma in a patient receiving long-term hemodialysis. Surgery 1999; 125: 239-240.
136. Santamaria I, AlvarezHernandez D, Jofre R, Polo JR, Menarguez J, CannataAndia JB. Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability. Kidney Int 2005; 67: 2267-2279.
137. Drüeke TB, Zhang P, Gogusev J. Apoptosis: background and possible role in secondary hyperparathyroidism (Invited Comment). Nephrol Dial Transplant 1997; 12: 2228-2233.
138. Parfitt AM. The hyperparathyroidism of chronic renal failure: a disorder of growth. Kidney Int 1997; 52: 3-9.
139. Canalejo A, Almaden Y, Torregrosa V, et al. The in vitro effect of calcitriol on parathyroid cell proliferation and apoptosis. J Amer Soc Nephrol 2000; 11: 1865-1872.
140. Jara A, Gonzalez S, Felsenfeld AJ, et al. Failure of high doses of calcitriol and hypercalcaemia to induce apoptosis in hyperplastic parathyroid glands of azotaemic rats. Nephrol Dial Transplant 2001; 16: 506-12.
141. Shiizaki K, Negi S, Hatamura I, et al. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol 2005; 16: 97-108.
142. Zhang P, Duchambon P, Gogusev J, et al. Apoptosis in parathyroid hyperplasia of patients with primary or secondary uremic hyperparathyroidism. Kidney Int 2000; 57: 437-445.
143. Heidenreich S, Schmidt M, Bachmann J, Harrach B. Apoptosis of monocytes cultured from long-term hemodialysis patients. Kidney Int 1996; 49: 792-799.
144. Fadda SG, Massry SG. Chronic renal failure is a state of cellular calcium toxicity (Review). Am J Kidney Dis 1993; 21: 81-86.
145. Carracedo J, Ramirez R, Martin-Malo A, Rodriguez M, Aljama P. Nonbiocompatible hemodialysis membranes induce apoptosis in mononuclear cells: the role of G-proteins. J Am Soc Nephrol 1998; 9: 46-53.
146. Lewin E, Wang W, Olgaard K. Reversibility of experimental secondary hyperparathyroidism. Kidney Int 1997; 52: 1232-1241.
147. Henry HL, Taylor AN, Norman AW. Response of chick parathyroid glands to the vitamin D metabolites, 1,25-dihydroxycholecalciferol and 24,25-dihydroxycholecalciferol. J Nutr 1977; 107: 1918-1926.
148. Cloutier M, Brossard JH, Gascon-Barre M, D'Amour P. Lack of involution of hyperplastic parathyroid glands in dogs: adaptation via a decrease in the calcium stimulation set point and a change in secretion profile. J Bone Miner Res 1994; 9: 621-629.
149. Martin D, Miller G, Colloton M, Shatzen E, Lacey D. Cincacalcet HCl decreases parathyroid hyperplasia in a rodent model of chronic renal insufficiency (CRI). J Am Soc Nephrol 2003; 14: 462A.
150. Shiizaki K, Hatamura I, Negi S, et al. Percutaneous maxacalcitol injection therapy regresses hyperplasia of parathyroid and induces apoptosis in uremia. Kidney Int 2003; 64: 992-1003.
151. Nylen E, Shah A, Hall J. Spontaneous remission of primary hyperparathroidism from parathroid apoplexy. J Clin Endocrinol Metab 1996; 81: 1326-1328.
152. Fukagawa M, Okazaki R, Takano K, et al. Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 1990; 323: 421-422.
153. Quarles LD, Yohay DA, Carroll BA, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 1994; 45: 1710-1721.
154. Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E. Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 1994; 68: 221-228.
155. Okuno S, Ishimura E, Kitatani K, et al. Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 2003; 18: 2613-21.
156. Martin KJ, Hruska KA, Lewis J, Anderson C, Slatopolsky E. The renal handling of parathyroid hormone: role of peritubular uptake and glomerular filtration. J Clin Invest 1977; 60: 808-814.
157. Hilpert J, Nykjaer A, Jacobsen C, et al. Megalin antagonizes activation of the parathyroid hormone receptor. J Biol Chem 1999; 274: 5620-5625.
158. Freitag JJ, Martin KJ, Hruska KA, Slatopolsky E. Impaired parathyroid hormone metabolism in patients with chronic renal failure. N Engl J Med 1978; 298: 29-34.
159. Hruska KA, Kopelman R, Rutherford WE, Klahr S, Slatopolsky E. Metabolism of immunoreactive parathyroid hormone in the dog: the role of the kidney and the effects of chronic renal disease. J Clin Invest 1975; 56: 39-46.
160. Martin KJ, Hruska KA, Freitag JJ, Klahr S, Slatopolsky E. The peripheral metabolism of parathyroid hormone in patients with chronic renal failure. N Engl J Med 1979; 301: 1092-1098.
161. Daugaard H, Egfjord M, Lewin E, Olgaard K. Metabolism of intact PTH by isolated perfused kidney and liver from uremic rats. Exp Nephrol 1994; 2: 240-248.
162. Fukagawa M, Kazama JJ, Shigematsu T. Skeletal resistance to PTH as a basic abnormality underlying uremic bone diseases. Am J Kidney Dis 2001; 38: S152-5.
163. Kazama JJ, Shigematsu T, Yano K, et al. Increased circulating levels of osteoclastogenesis inhibitory factor (osteoprotegerin) in patients with chronic renal failure. Am J Kidney Dis 2002; 39: 525-32.
164. Smogorzewski M, Tian J, Massry SG. Down-regulation of PTH-PTHrP receptor of heart in CRF: role of [Ca2+]i. Kidney Int 1995; 47: 1182-1186.
165. Ureña P, Ferreira A, Morieux C, Drüeke TB, deVernejoul MC. PTH/PTHrP receptor mRNA is down-regulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant 1996; 11: 2008-2016.
166. Ureña P, Kubrusly M, Mannstadt M, et al. The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 1994; 45: 605-611.
167. Ureña P, Mannstadt M, Hruby M, et al. Parathyroidectomy does not prevent the renal PTH/PTHrP receptor down-regulation in uremic rats. Kidney Int 1995; 47: 1797-1805.
168. Picton ML, Moore PR, Mawer EB, et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int 2000; 58: 1440-1449.
169. Langub MC, MonierFaugere MC, Qi QL, Geng Z, Koszewski NJ, Malluche HH. Parathyroid hormone/parathyroid hormone-related peptide type 1 receptor in human bone. J Bone Miner Res 2001; 16: 448-456.
170. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM. PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 2006; 47: 149-56.
171. Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity ? Am J Kidney Dis 1998; 32: 513-518.
172. Cohen-Solal ME, Boudailliez B, Sebert JL, Westeel PF, Bouillon R, Fournier A. Comparison of intact, mid region and carboxyterminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients. J Clin Endocrinol Metab 1991; 73: 516-524.
173. Quarles LD, Lobaugh B, Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992; 75: 145-150.
174. Wang M, Hercz G, Sherrard DJ, Maloney NA, Segre GV, Pei Y. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 1995; 26: 836-844.
175. Brossard JH, Cloutier M, Roy L, Lepage R, Gascon-Barré M, D'Amour P. Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996; 81: 3923-3929.
176. Lepage R, Roy L, Brossard JH, et al. A non-(1-84) circulating parathyroid hormone (PTH fragment interferes significantly with intact commercial PTH assay measurements in uremic samples. Clin Chem 1998; 44: 805-809.
177. Langub MC, Monier-Faugere MC, Wang G, Williams JP, Koszewski NJ, Malluche HH. Administration of PTH-(7-84) antagonizes the effects of PTH-(1-84) on bone in rats with moderate renal failure. Endocrinology 2003; 144: 1135-8.
178. Santamaria R, Almaden Y, Felsenfeld A, et al. Dynamics of PTH secretion in hemodialysis patients as determined by the intact and whole PTH assays. Kidney Int 2003; 64: 1867-73.
179. John MR, Goodman WG, Gao P, Cantor TL, Salusky IB, Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: Implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999; 84: 4287-4290.
180. MonierFaugere MC, Geng ZP, Mawad H, et al. Improved assessment of bone turnover by the PTH-(1-84) large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468.
181. Coen G, Bonucci E, Ballanti P, et al. PTH 1-84 and PTH "7-84" in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40: 348-54.
182. Lehmann G, Stein G, Huller M, Schemer R, Ramakrishnan K, Goodman WG. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry. Kidney Int 2005; 68: 1206-1214.
183. Reichel H, Esser A, Roth HJ, Schmidt-Gayk H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 2003; 18: 759-68.
184. Salusky IB, Goodman WG, Kuizon BD, et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63: 1801-1808.
185. Kramer H, Toto R, Peshock R, Cooper R, Victor R. Association between chronic kidney disease and coronary artery calcification: The Dallas Heart study. J Am Soc Nephrol 2005; 16: 507-13.
186. Raggi P. Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease. Nephrol Dial Transplant 2002; 17: (in press).
187. London GM, Guerin AP, Marchais SJ, Metivier F, Pannier B, Adda H. Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-40.
188. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int 1999; 56: 383-392.
189. Tsuchihashi K, Takizawa H, Torii T, et al. Hypoparathyroidism potentiates cardiovascular complications through disturbed calcium metabolism: Possible risk of vitamin D-3 analog administration in dialysis patients with end-stage renal disease. Nephron 2000; 84: 13-20.
190. Shao JS, Cheng SL, CharltonKachigian N, Loewy AP, Towler DA. Teriparatide (Human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem 2003; 278: 50195-50202.
191. Moe SM, Sprague SM, Cunningham J, et al. Long-term treatment of secondary hyperparathyroidism (HPT) with the calcimimetic cinacalcet HCl (Abstract SA-PO753). J Am Soc Nephrol 2003; 14: 463A.
192. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: 1-201.
193. Brown EM, Pollak M, Riccardi D, Hebert SC. Cloning and characterization of an extracellular Ca2+ -sensing receptor from parathyroid and kidney: new insights into the physiology and pathophysiology of calcium metabolism (Editorial). Nephrol Dial Transplant 1994; 9: 1703-1706.
194. Goodman WG, Frazao JM, Goodkin DA, Turner SA, Liu W, Coburn JW. A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 2000; 58: 436-45.
195. Goodman WG, Hladik GA, Turner SA, et al. The calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13: 1017-24.
196. Antonsen JE, Sherrard DJ, Andress DL. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure - rapid communication. Kidney Int 1998; 53: 223-227.
197. Colloton M, Shatzen E, Miller G, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int 2005; 67: 467-476.
198. Wada M, Furuya Y, Sakiyama J, et al. NPS R-568 halts or reverses osteitis fibrosa in uremic rats. Kidney Int 1997; 53: 448-453.
199. Lindberg JS, Moe SM, Goodman WG, et al. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int 2003; 63: 248-254.
200. Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14: 575-83.
201. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004; 350: 1516-25.
202. Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI(TM) bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005; 67: 760-771.
203. Moe SM, Cunningham J, Bommer J, et al. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl. Nephrol Dial Transplant 2005; 20: 2186-2193.
204. Cunningham J, Danese M, Olson K, Klassen P, Chertow GM. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793-1800.
205. Lorenzo V, Martin M, Rufino M, et al. Protein intake, control of serum phosphorus, and relatively low levels of parathyroid hormone in elderly hemodialysis patients. Am J Kidney Dis 2001; 37: 1260-6.
206. Argilés A, Kerr PG, Canaud B, Flavier JL, Mion C. Calcium kinetics and the long-term effects of lowering dialysate calcium concentration. Kidney Int 1993; 43: 630-640.
207. Cunningham J, Beer J, Coldwell RD, Noonan K, Sawyer N, Makin HLJ. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol. Nephrol Dial Transplant 1992; 7: 63-68.
208. Atik A, Ghazali A, Achard JM, et al. La déplétion relative en vitamine D native: un facteur de risque potentiel chez l'hémodialysé algérien de lésions radiologiques d'hyperparathyroïdie et d'ostéomalacie indépendant de la calcitriolémie. Néphrologie 1997; 18: 47-52.
209. Drueke TB. Calcimimetics versus vitamin D: what are their relative roles? Blood Purif 2004; 22: 38-43.
210. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-56.
211. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Amer Soc Nephrol 2005; 16: 1115-1125.
212. Drueke TB, McCarron DA. Paricalcitol as compared with calcitriol in patients undergoing hemodialysis. N Engl J Med 2003; 349: 496-9.
213. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. American Journal of Kidney Diseases 1997; 29: 66-71.
214. Slatopolsky EA, Burke SK, Dillon MA. RenaGel (R), a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299-307.
215. Nagano N, Miyata S, Abe M, et al. Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats. Kidney Int 2006; 69: 531-537.
216. Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nephrol Dial Transplant 2006; 21: 634-43.
217. Salusky IB, Goodman WG, Sahney S, et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Amer Soc Nephrol 2005; 16: 2501-2508.
218. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-52.
219. Asmus HG, Braun J, Krause R, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant 2005; 20: 1653-61.
220. Katsumata K, Kusano K, Hirata M, et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kidney Int 2003; 64: 441-450.
221. Cozzolino M, Staniforth ME, Liapis H, et al. Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia. Kidney Int 2003; 64: 1653-61.
222. Phan O, Ivanovski O, Nguyen-Khoa T, et al. Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005; 112: 2875-82.
223. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; S73-8.
224. Behets GJ, Verberckmoes SC, Oste L, et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005; 67: 1830-6.
225. Lacour B, Lucas A, Auchere D, Ruellan N, de Serre Patey NM, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67: 1062-9.
226. Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004; 65: 1099-1104.
227. Lefebvre A, Vernejoul MCD, Gueris J, Goldfarb B, Graulet AM, Morieux C. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989; 36: 1112-1118.
228. Graham KA, Hoenich NA, Tarbit M, Ward MK, Goodship THJ. Correction of acidosis in hemodialysis patients increases the sensitivity of the parathyroid glands to calcium. J Am Soc Nephrol 1997; 8: 627-631.
229. Giangrande A, Castiglioni A, Solbiati L, Allaria P. US-guided percutaneous fine-needle ethanol injection into parathyroid glands in secondary hyperparathyroidism. Nephrol Dial Transplant 1992; 7: 412-420.
230. Kitakoa M, Fukagawa M, Ogata E, Kurokawa K. Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients. Kidney Int 1994; 46: 1110-1117.
231. Kakuta T, Fukagawa M, Fujisaki T, et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999; 33: 1091-9.
232. Fletcher S, Kanagasundaram NS, Rayner HC, et al. Assessment of ultrasound guided percutaneous ethanol injection and parathyroidectomy in patients with tertiary hyperparathyroidism. Nephrol Dial Transplant 1998; 13: 3111-7.
233. Young EW, Akiba T, Albert JM, et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004; 44: 34-8.
234. Gagné ER, Ureña P, Leite-Silva S, et al. Short and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992; 3: 1008-1017.
235. Stratton J, Simcock M, Thompson H, Farrington K. Predictors of recurrent hyperparathyroidism after total parathyroidectomy in chronic renal failure. Nephron Clin Pract 2003; 95: c15-22.
236. Malberti F, Marcelli D, Conte F, Limido A, Spotti D, Locatelli F. Parathyroidectomy in patients on renal replacement therapy: An epidemiologic study. J Amer Soc Nephrol 2001; 12: 1242-1248.
237. Kestenbaum B, Seliger SL, Gillen DL, et al. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int 2004; 65: 282-288.